Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

TS/A

From Wikipedia, the free encyclopedia

TS/A is a mouse mammary adenocarcinoma cell line established in the early 1980s from a spontaneous tumor of a retired breeder BALB/c female mouse.[1][2] In the 1990s it was widely used as a recipient cell line for the transduction of cytokine genes and other genes of immunological interest, to produce recombinant experimental vaccines that induced anti-tumor immunological responses.[3]

References

[edit]
  1. Nanni P, C De Giovanni, P-L Lollini, G Nicoletti, and G Prodi. 1983. "TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma". Clinical and Experimental Metastasis. 1(4): 373-80.
  2. De Giovanni C, Nicoletti G, Landuzzi L, Palladini A, Lollini PL, Nanni P. "Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model". Cancers (Basel). 2019 Nov 27;11(12).
  3. Allione A, M Consalvo, P Nanni, P-L Lollini, F Cavallo, M Giovarelli, M Forni, A Gulino, MP Colombo, P Dellabona, H Hock, T Blankenstein, FM Rosenthal, B Gansbacher, MC Bosco, T Musso, L Gusella, and Guido Forni. 1994. "Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants". Cancer Research. 54(23): 6022-6026.
[edit]